Show simple item record

dc.contributor.authorMurphy, R A*
dc.date.accessioned2008-12-03T15:19:37Z
dc.date.available2008-12-03T15:19:37Z
dc.date.issued2008-06-01
dc.identifier.citationThe emerging crisis of drug-resistant tuberculosis in South Africa: lessons from New York City. 2008, 46 (11):1729-32 Clin. Infect. Dis.en
dc.identifier.issn1537-6591
dc.identifier.pmid18426372
dc.identifier.doi10.1086/587903
dc.identifier.urihttp://hdl.handle.net/10144/41794
dc.description.abstractMultidrug-resistant tuberculosis and extensively drug-resistant tuberculosis have emerged as important infections in South Africa among patients infected with human immunodeficiency virus (HIV). In the face of this new epidemic, South Africa must rededicate itself to the task of tuberculosis control and treatment with a rapid, multifaceted approach. Priorities include expansion of second-line treatment capacity, investment in clinical laboratories, a system to ensure supervised treatment for all patients, and enhancement of infection control procedures. In New York City, where drug-resistant tuberculosis emerged 2 decades ago--also in the context of a large HIV-infected population and an underfunded public health infrastructure--similar steps were successful in leading to the rapid decrease in rates of drug resistance among tuberculosis isolates. With refinements based on local resource constraints, urgent measures could potentially arrest the alarming increase in multidrug-resistant and extensively drug-resistant tuberculosis cases in South Africa. Unlike many countries in sub-Saharan Africa, South Africa has the capacity to mount a rapid and large-scale response before drug-resistant tuberculosis envelops a much larger and far poorer region.
dc.language.isoenen
dc.rightsArchived with thanks to Clinical Infectious Diseases : an official publication of the Infectious Diseases Society of Americaen
dc.subject.meshAIDS-Related Opportunistic Infectionsen
dc.subject.meshAntiretroviral Therapy, Highly Activeen
dc.subject.meshCommunicable Diseases, Emergingen
dc.subject.meshExtensively Drug-Resistant Tuberculosisen
dc.subject.meshHIV Infectionsen
dc.subject.meshHumansen
dc.subject.meshSouth Africaen
dc.subject.meshTuberculosis, Multidrug-Resistanten
dc.titleThe emerging crisis of drug-resistant tuberculosis in South Africa: lessons from New York City.en
dc.contributor.departmentDivision of Infectious Diseases, Massachusetts General Hospital and Brigham and Women's Hospital, Boston, Massachusetts, USA. richard.murphy@newyork.msf.orgen
dc.identifier.journalClinical Infectious Diseasesen
refterms.dateFOA2019-03-04T12:10:09Z
html.description.abstractMultidrug-resistant tuberculosis and extensively drug-resistant tuberculosis have emerged as important infections in South Africa among patients infected with human immunodeficiency virus (HIV). In the face of this new epidemic, South Africa must rededicate itself to the task of tuberculosis control and treatment with a rapid, multifaceted approach. Priorities include expansion of second-line treatment capacity, investment in clinical laboratories, a system to ensure supervised treatment for all patients, and enhancement of infection control procedures. In New York City, where drug-resistant tuberculosis emerged 2 decades ago--also in the context of a large HIV-infected population and an underfunded public health infrastructure--similar steps were successful in leading to the rapid decrease in rates of drug resistance among tuberculosis isolates. With refinements based on local resource constraints, urgent measures could potentially arrest the alarming increase in multidrug-resistant and extensively drug-resistant tuberculosis cases in South Africa. Unlike many countries in sub-Saharan Africa, South Africa has the capacity to mount a rapid and large-scale response before drug-resistant tuberculosis envelops a much larger and far poorer region.


Files in this item

Thumbnail
Name:
Murphy NY CID.pdf
Size:
175.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record